Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).

1 finding from 1 review